Cold and flu season has gotten much more dangerous in recent years. Now, it’s more like cold-flu(A)-flu(B)-COVID-RSV season. The common cold remains an annoyance, but influenza, COVID-19 and respiratory syncytial virus can be life-threatening, or at least require hospitalization.
NJBIZ Conversations is now available as a podcast, as well. Subscribe to NJBIZ Conversations on Apple or Google Podcasts. Find direct links here: njbiz.podbean.com
That makes testing for those infections critically important, especially among vulnerable populations. Franklin Lakes-based BD – the former Becton Dickinson and Co. – has been at the forefront of the effort to make such test easier and more efficient. Early in February, the company received an Emergency Use Authorization from the U.S. Food and Drug Administration for its molecular diagnostic combination test for COVID-19, Influenza A+B and RSV, which it says will help to combat illness in current – and future – respiratory virus cycles.
In this edition of NJBIZ Conversations, BD Executive Vice President and President of Life Sciences Dave Hickey, describes the new test, its importance in combatting future outbreaks and other significant developments in the testing field.